ClinicalTrials.gg
Active, not recruitingNCT06442462Updated Feb 6, 2026

Study of SPG302 in Adults With Schizophrenia

A Phase 2 interventional study of SPG302 and Placebo in Schizophrenia, sponsored by Spinogenix. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Spinogenix · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Schizophrenia with a site in Australia — 3 open to participants now, 5 under way, 1 of them phase 3. Schizophrenia · Australia.

Planned enrollment
35th of 41
32 · median 167
Started
2024
the only one that year
Phase 2
6 of 46
none open now
Registered
45th of 46
by date

Among the 46 studies in Schizophrenia with a site in Australia, this one is the 35th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 2, and was the 45th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 46 studies in Schizophrenia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Schizophrenia with a site in Australia, or all of them as a file.
02

Study summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Read the detailed description

This Phase 2 study will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia. This is a randomized, placebo-controlled study of SPG302 administered once daily for six weeks.

This study will entail weekly visits to the study site for screening, study procedures, and receipt of investigational medication for use at home.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • synaptogenesis
  • synapse
  • dendritic spines
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65
  • Primary diagnosis of schizophrenia
  • Clinical laboratory values within normal range or \< 1.5 times
  • Currently prescribed only one antipsychotic medication, with stable dose for at least 4 weeks
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Any physical or psychological condition that prohibits study completion
  • Known cardiac disease
  • Active or history of in the past 5 years
  • History of CNS event or diagnosis in the past 5 years.
  • Receipt of products within 30 days
  • Blood donation within 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    Active SPG302 to be administered to participants with Schizophrenia

    Participants with schizophrenia will be randomized to receive SPG302 300 mg or placebo (two capsules of 150 mg) once daily for six weeks.

    Drug: SPG302

  • Placebo comparator
    Placebo comparator to be administered to participants with Schizophrenia

    Participants with schizophrenia will be randomized to receive SPG302 300 mg or placebo (two capsules of 150 mg) once daily for six weeks.

    Drug: Placebo

Interventions

  • DrugSPG302

    small synthetic molecule

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Positive and Negative Symptoms Scale (PANSS Score) as determined by clinician

    The PANSS is a scale to measure symptom severity of schizophrenia. Thirty symptoms of schizophrenia are evaluated by a clinician on a seven point sale, with 1 = absence of symptoms and 7 = extremely severe symptoms. This study will rate each score change by calculating the difference between baseline scale and completion of study intervention.

    Time frame: 6 weeks

  2. Electroencephalogram analysis to assess brain electrical activity

    Electroencephalograms (EEG) will provide a non-invasive measurement of brain activity. This test will be used to measure specific brain responses to stimuli, including attention and decision making electrical activity and detection of unexpected changes in the auditory environment.

    Time frame: 6 weeks

  3. Change in smooth pursuit eye tracking from baseline

    Participants will follow visual targets on a computer screen to assess for accuracy of following the item, and smoothness of eye movements. The visual target on the computer screen will follow several different tracking patterns and at various speeds.

    Time frame: 6 weeks

Secondary outcomes

  1. Safety and tolerability of SPG302 in patients with schizophrenia

    Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results (SAEs).

    Time frame: 6 weeks

  2. Change in Global Impressions Improvement scale as determined by clinician

    Change in the Clinical Global Impression of Improvement (CGI-I) is a 3-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. It is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients).

    Time frame: 6 weeks

  3. Change in MATRICS Consensus Cognitive Battery scale as determined by clinician

    The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains through timed assessments. The results of each assessment are summarized for overall cognitive performance. The average score is between 40-60, and a score below 40 indicates lower overall cognitive performance.

    Time frame: 6 weeks

  4. World Health Organization Quality of Life - Abbreviated Assessment Questionnaire-brief version from baseline

    This is a 26-item questionnaire which collects self-reported data on physical health, psychological health, social relationships, and environmental health. Each section is scored from 1 to 5, with higher scores indicate higher quality of life. Scores from each section are then added together for an overall score, with higher score indicating higher quality of life.

    Time frame: 6 weeks

  5. Change in Personal and Social Performance from baseline

    Personal and Social Performance (PSP) evaluates overall functioning in daily life. A higher score indicates higher functioning.

    Time frame: 6 weeks

07

Study locations

3 sites
  • CenExel CNS
    Garden Grove, California 92845, United States
  • Box Hill Hospital - Eastern Health
    Box Hill, Victoria 3128, Australia
  • Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Mar 2026, 19 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 19 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06442462
Lead sponsor
Spinogenix
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Aug 1, 2024
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

David Walling, MD
principal investigator · CenExel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPG-302

Start the discussion